Publication: 215

A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
      QxMD      Google Scholar   
Citation:
Oncologist vol 15 (12) 1310-1319
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
612  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, CA33601, CA77597, CA11789, U10 CA077658, CA77406, CA47577, CA35113, CA32291, U10 CA086726, CA41287, U10 CA035279, U10 CA045808, U10 CA031946, CA77651, U10 CA033601, U10 CA045389, CA45389, U10 CA077597, CA45808, CA35279, U10 CA045418, CA86726, U10 CA077440, CA77440, U10 CA041287, U10 CA035113, U10 CA077651, CA04326, CA08025, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31946  
Corr. Author:
 
Authors:
                       
Networks:
 
Study
CALGB-80603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Sunitinib, Phase II, Refractory, Pancreas adenocarcinoma, CALGB 80603